Loading company…
OMass Therapeutics is an Oxford biotech developing small molecule therapies for orphan diseases and immunological conditions.
Founded in 2016 and headquartered in Oxford, UK, OMass Therapeutics develops small molecule therapeutics for orphan diseases and immunological conditions. Its work centers on validated target ecosystems such as membrane proteins and intracellular complexes, using biochemistry, native mass spectrometry and custom chemistry. Co-founded by Idlir Liko and Jonathan Hopper, with Ros Deegan as CEO. In May 2023 it raised GBP 10 million in Series B funding from British Patient Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in